hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA

MLA

Aughton, K., et al. HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA. 2021. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1340016402&authtype=sso&custid=ns315887.

APA

Aughton, K., Elander, N., Evans, A., Jackson, R., Campbell, F., Costello, E., Halloran, C., Mackey, J., Scarfe, A., Valle, J., Carter, R., Cunningham, D., Tebbutt, N., Goldstein, D., Shannon, J., Glimelius, B., Hackert, T., Charnley, R., Anthoney, A., … Greenhalf, W. (2021). hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.

Chicago

Aughton, K, No Elander, A Evans, R Jackson, F Campbell, E Costello, Cm Halloran, et al. 2021. “HENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA MRNA.” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1340016402&authtype=sso&custid=ns315887.